-
Mashup Score: 35
SES AUA 2025 high-risk biochemically recurrent prostate cancer, enzalutamide monotherapy treatment, phase 3 EMBARK study, EMBARK (NCT02319837).
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
SES AUA 2025 high-risk biochemically recurrent prostate cancer, enzalutamide monotherapy treatment, phase 3 EMBARK study, EMBARK (NCT02319837).
Outcomes of men with high-risk biochemically recurrent #ProstateCancer who suspended enzalutamide monotherapy treatment in the phase 3 #EMBARK study. Presented by Paul Sieber, MD. #SESAUA25 written coverage by @zklaassen_md > https://t.co/RUkCB6q1KC @SES_AUA https://t.co/8WPoT3Bbu0